Therapeutic area intelligence for Electrolyte Replacement with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Recent signals(4)

RegulatoryJuly 28, 2026

FDA Approves Sodium Acetate Application ANDA220274 by Extrovis

The FDA has approved the application ANDA220274 for Sodium Acetate submitted by Extrovis.

RegulatoryJuly 15, 2026

FDA Accepts NDA for Sodium Bicarbonate by Amneal EU Ltd.

The FDA has accepted the New Drug Application (NDA) for Sodium Bicarbonate submitted by Amneal EU Ltd.

RegulatoryJuly 4, 2026

FDA Grants Approval for Sodium Bicarbonate ANDA220788 by ASPIRO

The FDA has granted approval for ANDA220788, a sodium bicarbonate formulation submitted by ASPIRO.

RegulatoryJune 23, 2026

FDA Accepts Supplement for POKONZA by Genus Lifesciences

The FDA has accepted a supplemental application for POKONZA, an electrolyte replacement therapy containing potassium chloride.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Metabolic Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.